Roche To Work On Reversing English Funding Rejection For SMA Drug
But Tecentriq Gets NICE Thumbs Up For NSCLC
Evrysdi could follow Spinraza and Zolgensma to become the third treatment for spinal muscular atrophy available on England’s National Health Service if Roche can agree on a lower price for the drug.
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
The English and Scottish health technology appraisal bodies NICE and the Scottish Medicines Consortium have given the green light to Novartis/Avexis’ costly gene therapy, Zolgensma.
The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.